Results 221 to 230 of about 9,625,606 (401)
Sheehan's syndrome complicated with Graves' disease in a woman with a 20-year history of hypothyroidism. [PDF]
Yan M, Zhang J, Wang Y, Wei H.
europepmc +1 more source
Hyperthyroid heart disease: Diagnostic and therapeutic aspects [PDF]
Reinwein, Dankwart+2 more
core +1 more source
The co‐delivery of mRNAs encoding a CD47 inhibitor and a cytokine cocktail (interleukins 12, 15, and 21) via lipid nanoparticles enables effective localized immunotherapy. This strategy not only suppresses tumor progression but also enhances type 1 conventional dendritic cell (cDC1) differentiation and activates CD8+ T cells, thereby inducing robust ...
Tao Jiang+14 more
wiley +1 more source
Management of Graves Disease With Co-Existing Duffy-Null Phenotype. [PDF]
Ferri GM+5 more
europepmc +1 more source
Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines
This review offers a comprehensive overview of pharmaceutical nanotechnology strategies to address limitations associated with the complex material basis and relative mild therapeutic efficacy of Chinese herbal medicines, and summarizes the advantages of these strategies.
Jiameng Li+11 more
wiley +1 more source
Massive Thymic Hyperplasia in Graves Disease. [PDF]
Chan C, Ryder S, Luong D, Puri G.
europepmc +1 more source
Modulation of class-II antigen expression in human thyroid epithelial cell cultures [PDF]
Arnholdt, H.+4 more
core +1 more source
In pancreatic ductal adenocarcinoma (PDAC), tumor‐intrinsic PD‐1 signaling activates the MET pathway, leading to the establishment of an immunosuppressive tumor microenvironment (TME). This MET‐driven signaling cascade promotes the selective accumulation of GITR+ regulatory T cells (Tregs), a highly immunosuppressive subset.
Jiande Han+16 more
wiley +1 more source